IRCT20220208053970N1 IRCT 2022-03-12 Shahre-kord University of Medical Sciences Effect of Toscilizumab and Infliximab on Covid 19 Comparison of the effectiveness of ACTEMRA (TOCILIZUMAB) and REMICADE (INFLIXIMAB) in patients with Covid19 2022-03-12 anticipated 40 Complete https://irct.ir/trial/61962 interventional Randomization: Not randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Blinding description: In this study, patients with Covid19 are divided into two groups and according to the treating physician, one of the drugs Tocilizumab and Infliximab is injected according to the inclusion criteria. In this study, patients are aware and satisfied to receive one of these two drugs, but they are blind to which of these drugs, but the doctor and other research team are aware of which drug to receive by which group. 2-3 covid19. Intervention 1: Intervention group 1: This group of patients with Covid19 who have received standard treatments ,receive tocilizumab brand name ACTEMRA and TEMZIVA from ROCHE PHARMA and ARIOGEN PHARMED factories at a dose of 8 mg / kg in one or two doses two days apart. Intervention 2: Intervention group 2: This group of patients with Covid19 who have received standard treatments, receive an infliximab brand name REMICADE from JANSSEN factory at a dose of 5 mg/kg. Yes - There is a plan to make this available What will be shared: All data from the study can be shared after being unidentified When: Access begins in the winter of 1401 To whom: The data will be available to researchers and academics Conditions: Access will be possible to assist with future studies and scientific reviews Where to obtain: Contact Dr. Amir Hossein Koohi to receive data amirh1391@gmail.com How to obtain: After introducing the applicant and stating the purpose of the information request, as well as the commitment not to use it anymore, it can be received via email. Comments: